
|Articles|October 15, 2006
New Products & Services
Irvine, CA-The Cryocare CN2 System from Endocare, Inc. has received 510K clearance from the FDA. The device uses the freezing capability of nitrogen at the point between gas and liquid-"critical nitrogen"-to destroy cancerous tissue quicker and more cost-effectively than argon can, according to the manufacturer. The speed and precision of this new technology can expedite procedures, Endocare says, because it is easy to use and it delivers a colder, more powerful ice ball at the end of the probes.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Nicole L. Miller, MD, FACS, on assessing patients after BPH treatment failure
4
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
5











